Scholars Journal of Applied Medical Sciences
Abbreviated Key Title: Sch J App Med Sci
ISSN 2347-954X (Print) | ISSN 2320-6691 (Online)
Journal homepage: https://saspublishers.com

OPEN ACCESS

Neurology

Blueprints of the Mind: Genetic Predictors and Pharmacogenomic Transformation of Psychiatric Treatment

Dr Fathi Moustafa Abdalla Eid[1*], Dr Mohammad Mazharuddin[2]

[1]Referral Triage Physician, Operations – Integrated Care & Continuity of Care, PHCC, Qatar
[2]MD Physician, Dip.in Neurology (UCL), MRCPsych (U.K), Consultant Psychiatrist, Leabaib Health Centre, Primary Health Care Corporation (PHCC), Doha, Qatar

DOI: https://doi.org/10.36347/sjams.2025.v13i06.017 | **Received:** 22.05.2025 | **Accepted:** 28.06.2025 | **Published:** 30.06.2025

***Corresponding author:** Dr Fathi Moustafa Abdalla Eid
Referral Triage Physician, Operations – Integrated Care & Continuity of Care, PHCC, Qatar

Abstract **Review Article**

Mental health disorders affect millions globally and present ongoing challenges in psychiatric care. Traditional treatments often rely on trial-and-error prescribing, which can delay effective therapy and lead to unnecessary side effects. Pharmacogenomics, the study of how genes influence drug response, offers a more personalised approach. It allows clinicians to tailor psychiatric medications and dosages based on individual genetic profiles. Integrating genetic information into psychiatric care has the potential to improve treatment outcomes and reduce adverse effects. Pharmacogenomics represents an important step toward personalised medicine in mental health. This review explores the role of pharmacogenomics in psychiatry. It examines key genetic markers involved in drug metabolism and response. We discuss the current clinical applications of pharmacogenomic testing, along with the ethical, logistical, and implementation challenges.

Keywords: Pharmacogenomics, Psychiatric Disorders, Personalised Medicine, Drug Metabolism, Treatment Outcomes.

INTRODUCTION

Psychiatric disorders, encompassing a wide spectrum of conditions such as depression, schizophrenia, bipolar disorder, and anxiety disorders, pose substantial challenges to global public health (Ingelman-Sundberg *et al.,* 2023). These conditions significantly impair an individual's cognitive, emotional, and behavioural functions, leading to decreased quality of life, increased disability, and higher mortality rates (Brazell *et al.,* 2002). Traditional psychiatric treatment often depends on observing symptoms and adjusting medications through trial and error. Such practices can lead to delays in finding the right therapy and may prolong a patient's distress. Despite advancements in psychiatric care, finding the right medication for each patient remains a complex and time-consuming process, frequently marked by side effects and limited efficacy (Giacomini *et al.,* 2012). Conventional prescribing strategies often lack the precision needed to address the intricate interplay of genetic, environmental, and lifestyle factors that contribute to an individual's response to psychiatric medications (Provenza *et al.,* 2019). Pharmacogenomics is an emerging field with growing relevance in psychiatry. It focuses on how genetic differences affect a person's response to medications. By using this information, clinicians can make more informed choices about drug selection and dosing. This approach may reduce side effects, improve treatment outcomes, and move psychiatric care toward a more personalised model.

Pharmacogenomics: A New Paradigm in Psychiatry

Pharmacogenomics involves analysing how genetic variations affect how individuals respond to drugs with the goal of maximising treatment efficacy and safety (Rollinson *et al.,* 2020). This field focuses on variation in genes affecting drug metabolism, drug transport, and drug targets, which can significantly impact how individuals respond to medications (Lally *et al.,* 2016). Insights from pharmacogenomic research are changing how psychiatric care is delivered. Instead of relying on trial and error, clinicians can develop treatment plans based on a patient's unique genetic makeup. This shift supports more precise and effective care. Identifying genetic markers linked to drug response helps guide clinical decisions. Clinicians can better predict which medications are likely to work, what doses may be effective, and who might face a higher risk of

side effects. The result supports safer and more targeted treatment.

This approach helps improve treatment outcomes while reducing unnecessary risks. It limits exposure to ineffective or harmful medications and lowers the chance of side effects. As a result, patients are more likely to stick with their treatment plans. Pharmacogenomics represents a shift toward precision medicine in psychiatry, aligning treatment strategies with the individual genetic characteristics of each patient (Lally & MacCabe, 2016).

Key Genetic Factors in Psychiatric Pharmacogenomics

Genetic differences have a significant impact on how people respond to psychiatric medications. Among these, single nucleotide polymorphisms are the most common type of variation influencing drug response (Chaudhary *et al.,* 2015). Variations in genes that code for drug-metabolising enzymes, like the cytochrome P450 family, can greatly affect how medications are broken down in the body. These differences influence how quickly a drug is processed and cleared, which can impact both its effectiveness and safety (Srivastav *et al.,* 2025). Genetic polymorphisms in these enzymes can change how well they work. As a result, people may be classified as poor, intermediate, normal, or ultrarapid metabolisers, depending on how quickly they process medications (Kassam *et al.,* 2005). These genetic differences can cause major changes in drug levels in the blood. This affects how well a medication works and how likely it is to cause side effects. People with slower enzyme activity may have higher drug concentrations and a greater risk of adverse effects. In contrast, those with faster enzyme activity may need higher doses to get the same benefit (Kalow, 1980). Genetic differences in drug transporters, such as P-glycoprotein, can affect how drugs move across cell membranes. This influences how medications are absorbed, distributed, and cleared from the body.

Cytochrome P450 (CYP) enzymes are also key players in drug metabolism. They help determine how psychiatric medications are processed. Variations in the genes that code for these enzymes can change how active they are. Such variation may lead to significant differences in drug levels and how well a treatment works—or how likely it is to cause side effects. Variations in CYP450 enzymes, particularly CYP2D6 and CYP2C19, have a strong impact on how antidepressants and antipsychotics are metabolised. These differences can influence both the effectiveness and safety of these medications.

Variants in the serotonin transporter gene (5-HTTLPR) have been linked to differences in how patients respond to antidepressants. These genetic differences affect serotonin uptake and its availability in the brain.

Similarly, variations in dopamine receptor genes—such as DRD2 and DRD3—are associated with how well antipsychotics work. They may also influence the likelihood of side effects, particularly in patients with schizophrenia (Roden, 2006).

The HLA-B1502 gene is closely related to serious skin reactions like Stevens-Johnson syndrome and toxic epidermal necrolysis caused by carbamazepine, particularly in people of Asian descent. Because of this risk, it is advised to test for HLA-B1502 before beginning carbamazepine in these groups to help avoid serious side effects (Baietto *et al.,* 2014).

Current Applications of Pharmacogenomics in Psychiatry

Pharmacogenomic testing is becoming more common in psychiatric practice. It helps guide medication choices and dosing by analyzing key genes involved in drug metabolism and responses. Several clinical assays are now available to support this approach in routine care. These tests examine genetic variations in drug-metabolising enzymes, transporters, and drug targets. The results give clinicians important insights to help personalise treatment plans and improve outcomes. Pharmacogenomic testing is already shaping clinical decision-making. It helps clinicians choose the right medications and adjust dosages based on each patient's genetic profile. Pharmacogenomics has value in treating conditions like depression, anxiety disorders, schizophrenia, and bipolar disorder. Clinical guidelines now support its use in certain situations, helping tailor treatment based on genetic insights.

Examples of Pharmacogenomic Testing in Psychiatry

Pharmacogenomics Testing Platforms: GeneSight, AmpliChip CYP450 Test, and ProgeneDx are some of the commonly used platforms (Brazell *et al.,* 2002).

The GeneSight test analyses genetic variations in multiple genes involved in drug metabolism and response. These include CYP2D6, CYP2C19, and SLC6A4. It provides clinicians with useful guidance when selecting medications for depression, anxiety, and other psychiatric conditions.

Clinical practice commonly uses CYP2D6 and CYP2C19 genotyping. It helps predict how a patient will metabolise antidepressants, such as selective serotonin reuptake inhibitors and tricyclic antidepressants. This information supports safer and more effective prescribing.

HLA-B1502 testing is critical before starting carbamazepine, especially in individuals of Asian descent. It helps prevent severe skin reactions such as Stevens-Johnson syndrome. Research shows that using pharmacogenomic testing in psychiatric care can

improve outcomes. Benefits include higher remission rates, fewer side effects, and greater patient satisfaction. However, the usefulness of these tests can vary. It depends on the type of test, the patient population, and the clinical setting. This demonstrates the value of interpreting results carefully and using them alongside clinical judgement.

Genetic testing of drug-metabolising enzymes can prevent a wide range of adverse reactions (Gershon *et al.,* 2014). Such tests offer a precise genetic map that can guide therapeutic interventions and avoid side effects (Lonetti *et al.,* 2015). Advances in genomic technology now allow researchers to scan the entire human genome for variants that may influence drug metabolism and activity. As this field grows, many more relevant genetic markers are expected to be identified in the coming years (Lonetti *et al.,* 2015; Polifka & Friedman, 2002). The combination of genome-wide association studies and advanced genomic technologies has greatly sped up the discovery of genetic factors that influence drug response. These tools have made it easier to uncover how genes affect treatment outcomes.

AmpliChip CYP450: The AmpliChip CYP450 was one of the first pharmacogenomic tests approved by the FDA. It analyses variations in the CYP2D6 and CYP2C19 genes to help predict how a person will metabolise certain medications.

ProgeneDx offers personalised medicine solutions with a focus on pharmacogenomic testing. Its services cover multiple therapeutic areas, including psychiatry, to support tailored treatment decisions.

CNSDose is a commercially available test that examines several genes related to the metabolism and transport of psychiatric medications. It helps guide personalised treatment by identifying genetic factors that may influence drug response.

The Clinical Pharmacogenomics Implementation Consortium (CPIC) provides key guidance for using pharmacogenomic information in practice. These guidelines help standardise how test results are interpreted and applied in clinical care. CPIC offers free, peer-reviewed, and evidence-based recommendations for specific gene–drug pairs.

Although pharmacogenomics has advanced significantly, only a limited number of gene–drug pairs have well-established clinical guidelines to support prescribing decisions (Holmes *et al.,* 2009). The Dutch Pharmacogenetics Working Group (DPWG) provides genotype-based recommendations for adjusting drug doses, based on current scientific evidence. DPWG guidelines provide genotype-based recommendations for drug dose adjustments based on the available scientific evidence. The FDA provides information on drugs with pharmacogenomic labels.

Challenges and Ethical Considerations

Integrating pharmacogenomics into psychiatric care comes with several challenges. There is a need for stronger clinical evidence, consistent testing methods, and better education for healthcare providers.

A major barrier is the lack of large-scale randomised controlled trials that clearly show the clinical value and cost-effectiveness of pharmacogenomic testing in psychiatry. Small sample sizes or weak methodologies limit many current studies, making it difficult to reach firm conclusions.

Clinical implementation is further limited by practical barriers. Cost and accessibility remain major barriers. Testing can be expensive, and insurance coverage or access to testing facilities may be limited in some regions.

Lack of awareness and education also affects adoption. Many healthcare providers lack adequate training to interpret pharmacogenomic results or apply them in clinical settings

Ethical and privacy concerns further complicate implementation. The collection of genetic data raises important questions about confidentiality, data protection, and the risk of discrimination in areas like insurance and employment.

Data interpretation and clinical integration pose significant challenges in pharmacogenomics. Translating genetic test results into clinical decisions requires more than just the genetic data itself. Clinicians must also consider patient characteristics, drug interactions, and comorbidities. Applying genetic information to treatment plans can be complex and often requires specialist knowledge (Benke & Benke, 2018). There is also a risk of misinterpreting or overestimating the influence of certain genetic variants, which may lead to inappropriate treatment choices.

In educational settings, disclosing a student's behavioural genetic profile introduces additional concerns (Sabatello, 2018). It is important to consider environmental and systemic factors that contribute to psychiatric conditions. Moreover, attention must be given to the ethical, legal, and social implications of using genetic data to prevent potential harm (DeRenzo *et al.,* 2020; Procter, 2002).

Future Directions in Pharmacogenomics

Future research in pharmacogenomics should aim to identify new genetic variants linked to drug response. There is also a need to develop testing platforms that are more comprehensive, affordable, and accessible. Large-scale clinical trials will be essential to confirm the value of pharmacogenomic testing in routine psychiatric care.

Further studies should explore how pharmacogenomics can help personalise treatment for a wider range of psychiatric disorders, including bipolar disorder, schizophrenia, and attention-deficit/hyperactivity disorder. One promising area is the use of polygenic risk scores, which combine the effects of multiple genetic variants into a single score to predict treatment outcomes (Laing *et al.,* 2011).

Another important direction involves integrating pharmacogenomics with other omics technologies, such as transcriptomics, proteomics, and metabolomics. This combined approach may offer a more complete understanding of the biological processes behind drug response and improve the accuracy of personalised treatment models (Manuck & McPherson, 2016).

The ultimate goal is to improve outcomes by tailoring medication and dosing to the individual's genetic profile (Liao & Tsai, 2013). As digital health technologies evolve, linking pharmacogenomic data to electronic health records and clinical decision support systems will allow smoother integration into real-time clinical practice.

Moreover, the combination of pharmacogenomics with mobile health apps and wearable sensors could enable real-time tracking of medication effects and support personalised dose adjustments (Williams *et al.,* 2015). This could lead to more dynamic and responsive treatment plans.

Pharmacogenomics may also help uncover new drug targets by identifying biological pathways involved in medication response. Such findings could lead to the development of more effective and focused therapies. Identifying subgroups of patients likely to benefit from specific drugs will also improve the design of clinical trials.

Long-term outcomes are another key area. We need more research to determine whether pharmacogenomic profiles can predict sustained treatment success or identify those at higher risk for adverse effects. Although many biomarkers have been proposed, none yet meet the sensitivity and specificity needed for routine clinical use (Dean, 2017).
Finally, successful global implementation will require coordinated policy efforts. International collaboration and standardisation of testing methods and reporting practises will be crucial to ensure safe and effective use of pharmacogenomics worldwide.

CONCLUSION

Pharmacogenomics marks a major shift in psychiatric care, moving toward more personalised and precise treatment. By using genetic information to guide medication choices and dosing, clinicians can improve therapeutic outcomes and reduce the risk of adverse effects (Al-Ghoul & Valdes, 2008). This approach offers a promising path for tailoring care to each patient's unique genetic profile.

Integrating pharmacogenomics with clinical and environmental data allows for more informed and individualised decision-making. Such an approach can help minimise side effects and increase treatment success for patients with mental health conditions (Erickson, 1998).

However, several challenges remain. These include cost barriers, the need for provider education, complexities in interpreting genetic data, and important ethical concerns. Despite these obstacles, the long-term benefits are significant. As research continues, we will gain deeper insight into how genes interact with medications—improving not only treatment outcomes but also our understanding of psychiatric disorders themselves.

With sustained research, policy support, and clinical training, pharmacogenomics is poised to become an integral part of mainstream psychiatric practice. Its potential to transform mental health care into a more effective, safe, and patient-centered discipline is increasingly within reach.

REFERENCES

- Al-Ghoul, M., & Valdes, R. (2008). Fundamentals of Pharmacology and Applications in Pharmacogenetics [Review of Fundamentals of Pharmacology and Applications in Pharmacogenetics]. Clinics in Laboratory Medicine, 28(4), 485. Elsevier BV. https://doi.org/10.1016/j.cll.2008.07.001
- Baietto, L., Corcione, S., Pacini, G., Perri, G. D., D'Avolio, A., & Rosa, F. G. D. (2014). A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics? [Review of A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?]. Current Drug Metabolism, 15(6), 581. Bentham Science Publishers. https://doi.org/10.2174/1389200215666140605130935
- Benke, K. K., & Benke, G. (2018). Artificial Intelligence and Big Data in Public Health. International Journal of Environmental Research and Public Health, 15(12), 2796. https://doi.org/10.3390/ijerph15122796
- Brazell, C., Freeman, A., & Mosteller, M. (2002). Maximizing the value of medicines by including pharmacogenetic research in drug development and surveillance [Review of Maximizing the value of medicines by including pharmacogenetic research in drug development and surveillance]. British Journal

of Clinical Pharmacology, 53(3), 224. Wiley. https://doi.org/10.1046/j.0306-5251.2001.01556.x

- Chaudhary, R., Singh, B., Kumar, M., Gakhar, S. K., Saini, A. K., Parmar, V. S., & Chhillar, A. K. (2015). Role of single nucleotide polymorphisms in pharmacogenomics and their association with human diseases [Review of Role of single nucleotide polymorphisms in pharmacogenomics and their association with human diseases]. Drug Metabolism Reviews, 47(3), 281. Taylor & Francis. https://doi.org/10.3109/03602532.2015.1047027
- Dean, C. E. (2017). Social inequality, scientific inequality, and the future of mental illness [Review of Social inequality, scientific inequality, and the future of mental illness]. Philosophy Ethics and Humanities in Medicine, 12(1). BioMed Central. https://doi.org/10.1186/s13010-017-0052-x
- DeRenzo, E. G., Singer, E. A., & Moss, J. (2020). Special issues raised by evolving areas of clinical research. In Elsevier eBooks (p. 271). Elsevier BV. https://doi.org/10.1016/b978-0-12-386935-7.00014-1
- Erickson, R. P. (1998). From "magic bullet" to "specially engineered shotgun loads": the new genetics and the need for individualized pharmacotherapy [Review of From "magic bullet" to "specially engineered shotgun loads": the new genetics and the need for individualized pharmacotherapy]. BioEssays, 20(8), 683. Wiley. https://doi.org/10.1002/(sici)1521-1878(199808)20:8<683::aid-bies12>3.0.co;2-v
- Gershon, E. S., Alliey-Rodriguez, N., & Grennan, K. (2014). Ethical and public policy challenges for pharmacogenomics. Dialogues in Clinical Neuroscience, 16(4), 567. https://doi.org/10.31887/dcns.2014.16.4/egershon
- Giacomini, K. M., Yee, S. W., Ratain, M. J., Weinshilboum, R. M., Kamatani, N., & Nakamura, Y. (2012). Pharmacogenomics and Patient Care: One Size Does Not Fit All [Review of Pharmacogenomics and Patient Care: One Size Does Not Fit All]. Science Translational Medicine, 4(153). American Association for the Advancement of Science. https://doi.org/10.1126/scitranslmed.3003471
- Holmes, M. V., Shah, T., Vickery, C., Smeeth, L., Hingorani, A. D., & Casas, J. P. (2009). Fulfilling the Promise of Personalized Medicine? Systematic Review and Field Synopsis of Pharmacogenetic Studies [Review of Fulfilling the Promise of Personalized Medicine? Systematic Review and Field Synopsis of Pharmacogenetic Studies]. PLoS ONE, 4(12). Public Library of Science. https://doi.org/10.1371/journal.pone.0007960
- Ingelman-Sundberg, M., Nebert, D. W., & Lauschke, V. M. (2023). Emerging trends in pharmacogenomics: from common variant associations toward comprehensive genomic profiling. Human Genomics, 17(1). https://doi.org/10.1186/s40246-023-00554-9
- Kalow, W. (1980). Pharmacogenetics of drug metabolism. Trends in Pharmacological Sciences, 1(2), 403. https://doi.org/10.1016/0165-6147(80)90063-2
- Kassam, S., Meyer, P., Corfield, A. P., Mikuz, G., & Sergi, C. (2005). Single Nucleotide Polymorphisms (SNPs): History, Biotechnological Outlook and Practical Applications. Current Pharmacogenomics, 3(3), 237. https://doi.org/10.2174/1570160054864021
- Laing, R. E., Hess, P., Shen, Y., Wang, J., & Hu, S. X. (2011). The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine [Review of The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine]. Current Drug Metabolism, 12(5), 460. Bentham Science Publishers. https://doi.org/10.2174/138920011795495268
- Lally, J., Gaughran, F., Timms, P., & Curran, S. (2016). Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics [Review of Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics]. Pharmacogenomics and Personalized Medicine, 117. Dove Medical Press. https://doi.org/10.2147/pgpm.s115741
- Lally, J., & MacCabe, J. H. (2016). Personalised approaches to pharmacotherapy for schizophrenia. BJPsych Advances, 22(2), 78. https://doi.org/10.1192/apt.bp.114.013433
- Liao, W., & Tsai, F. (2013). Personalized medicine: A paradigm shift in healthcare. Biomedicine, 3(2), 66. https://doi.org/10.1016/j.biomed.2012.12.005
- Lonetti, A., Fontana, M. C., Martinelli, G., & Iacobucci, I. (2015). Single Nucleotide Polymorphisms as Genomic Markers for High-Throughput Pharmacogenomic Studies. Methods in Molecular Biology, 143. https://doi.org/10.1007/978-1-4939-3136-1_11
- Manuck, T. A., & McPherson, J. (2016). Genomics of Preterm Birth—Evidence of Association and Evolving Investigations [Review of Genomics of Preterm Birth—Evidence of Association and Evolving Investigations]. American Journal of Perinatology, 33(3), 222. Thieme Medical Publishers (Germany). https://doi.org/10.1055/s-0035-1571144
- Polifka, J. E., & Friedman, J. M. (2002). Medical genetics: 1. Clinical teratology in the age of genomics. PubMed, 167(3), 265. https://pubmed.ncbi.nlm.nih.gov/12186175
- Procter, A. (2002). The ethics of genetic testing of families. Current Paediatrics, 12(6), 453. https://doi.org/10.1054/cupe.2002.0341
- Provenza, N. R., Matteson, E., Allawala, A., Barrios-Anderson, A., Sheth, S. A., Viswanathan, A., McIngvale, E., Storch, E. A., Frank, M. J.,

McLaughlin, N., Cohn, J. F., Goodman, W. K., & Borton, D. A. (2019). The Case for Adaptive Neuromodulation to Treat Severe Intractable Mental Disorders. Frontiers in Neuroscience, 13. https://doi.org/10.3389/fnins.2019.00152

- Roden, D. M. (2006). Pharmacogenomics: Challenges and Opportunities [Review of Pharmacogenomics: Challenges and Opportunities]. Annals of Internal Medicine, 145(10), 749. American College of Physicians. https://doi.org/10.7326/0003-4819-145-10-200611210-00007
- Rollinson, V., Turner, R. M., & Pirmohamed, M. (2020). Pharmacogenomics for Primary Care: An Overview [Review of Pharmacogenomics for Primary Care: An Overview]. Genes, 11(11), 1337. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/genes11111337
- Sabatello, M. (2018). A Genomically Informed Education System? Challenges for Behavioral Genetics. The Journal of Law Medicine & Ethics, 46(1), 130. https://doi.org/10.1177/1073110518766027
- Srivastav, A. K., Mishra, M. K., Lillard, J. W., & Singh, R. (2025). Transforming Pharmacogenomics and CRISPR Gene Editing with the Power of Artificial Intelligence for Precision Medicine [Review of Transforming Pharmacogenomics and CRISPR Gene Editing with the Power of Artificial Intelligence for Precision Medicine]. Pharmaceutics, 17(5), 555. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/pharmaceutics17050555
- Williams, J. K., Katapodi, M. C., Starkweather, A., Badzek, L., Cashion, A. K., Coleman, B., Fu, M. R., Lyon, D. E., Weaver, M. T., & Hickey, K. T. (2015). Advanced nursing practice and research contributions to precision medicine. Nursing Outlook, 64(2), 117. https://doi.org/10.1016/j.outlook.2015.11.009